This retrospective cohort-based study assessed the change in glycated haemoglobin A1C (HbA 1C) in patients with type 2 diabetes, with existing prescriptions for oral antidiabetic drugs (OADs), prescribed insulin versus those prescribed subsequent OADs. A cohort of patient records drawn from the The Health Improvement Network (THIN) database was stratified by maximum concurrent number of OADs. Of 128,568 unique patient records identified, 67.7% (n=87,057) had received at least one OAD, 17.4% (n=15,138) of these patients progressed to insulin therapy. Mean HbA1C at insulin initiation was 9.5% (one OAD), 9.6% (two), 9.7% (three) and 10.1% (four), with an average HbA 1C increase of 0.7% prior to insulin initiation. The greatest improvement in HbA1C was achieved with insulin therapy. A threshold HbA 1C value of 8.5% above which OAD escalation is unlikely to achieve a target HbA1C ≤ 7.0% is seen. In patients not achieving HbA1C targets with OADs only, insulin-based regimens should be considered in preference to adding more or multiple OADs.Br J Diabetes Vasc Dis 2010;10:178—182.
UK Prospective Diabetes Study (UKPDS) Group.Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet1998;352:837-53.
2.
Epidemiology of Diabetes Interventions and Complications (EDIC) Research Group.Epidemiology of Diabetes Interventions and Complications (EDIC). Design, implementation, and preliminary results of a long-term follow-up of the Diabetes Control and Complications Trial cohort. Diabetes Care1999;22:99-111.
3.
The Diabetes Control and Complications Trial Research Group.The effect of intensive diabetes treatment on the development and progression of long term complications in insulin dependent diabetes. N Engl J Med1993;329:978-86.
4.
The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group.Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med2005;353:2643-53.
5.
Nathan DM, Buse JB, Davidson MB et al. Medical management of hyperglycaemia in type 2 diabetes mellitus: A consensus algorithm for the initiation and adjustment of therapy. Diabetes Care2009;32: 193-203.
6.
The Action to Control Cardiovascular Risk in Diabetes Study Group.Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med2008;358:2545-59.
7.
The ADVANCE Collaborative Group.Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med2008;358:2560-72.
8.
Duckworth W. , Abraira C., Moritz T. et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med2009; 360:129-39.
9.
Department of Health.Quality and Outcomes Framework (QOF), 2009. http://www.dh.gov.uk/en/Healthcare/Primarycare/Primarycarecontracting/QOF/index.htm (Accessed 11 November 2009)
10.
Turner RC, Cull CA, Holman RRGlycemic control with diet, sulfonylurea, metformin and insulin in patients with type 2 diabetes. Progressive requirement for multiple therapies. UKPDS 49. JAMA1999;281:2005-12.
11.
Brown, JA, Nichols GA, Perry A.The burden of treatment failure in type 2 diabetes. Diabetes Care2004;27:1535-40.
12.
Rubino A., McQuay LJ, Gough SC et al. Delayed initiation of subcutaneous insulin therapy after failure of oral glucose-lowering agents in patients with type 2 diabetes: a population-based analysis in the UK. Diabet Med2007;24:1412-18.
13.
Krentz AJ, Bailey CJOral antidiabetic agents: current role in type 2 diabetes mellitus . Drugs2005;65:385-411.
14.
Poole CD, Tetlow T., McEwan P. et al. The prescription cost of managing people with type 1 and type 2 diabetes following initiation of treatment with either insulin glargine or insulin detemir in routine general practice in the UK: A retrospective database analysis. Curr Med Res Opin2007;23(suppl 1):S41-8.
15.
Currie CJ, Poole CD, Tetlow T. et al. The outcome of care in people with type 1 and type 2 diabetes following switching to treatment with either insulin glargine or insulin detemir in routine general practice in the UK: A retrospective database analysis. Curr Med Res Opin2007;23(suppl 1):S33-9. <AQ3>
16.
Pinheiro J. , Bates DMMixed Effects Models in S and S-PLUS. New York: Springer Verlag, 2000 .
17.
National Institute of Health and Clinial Excelence. Diabetes, Type 2 diabetes: blood glucose. London: NICE, 2002. http://www.nice.org.uk/Guidance/G (Accessed 3 September 2009)
18.
National Institute of Health and Clinial Excelence.Diabetes, Type 2 (update). London: NICE, 2008. http://www.nice.org.uk/Guidance/CG66 (Accessed: 3 September 2009)
19.
BMA.QOF Changes and new indicators for 2009/10. London: BMA, 2008. http://www.bma.org.uk/employmentandcontracts/independent_contractors/quality_outcomes_framework/QoFchangesOct08.jsp (Accessed 3 September 2009)
20.
Peyrot M., Rubin RR, Lauritzen T. et al. Resistance to insulin therapy among patients and providers. Diabetes Care2005;28:2673-9.
21.
Surwit RS, van Tilburg MAL, Parekh PI et al. Treatment regimen determines the relationship between depression and glycemic control. Diabetes Res Clin Practice2005;69:78-80.
22.
UK Prospective Diabetes Study (UKPDS) Group.Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet1998;352:854-65.
